Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Dec 28;29(4):543.e5–543.e9. doi: 10.1016/j.cmi.2022.12.016

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

PMC Copyright notice

Fig. 1 — Time to negative conversion of nasopharyngeal SARS-CoV-2 PCR and changes in cycle threshold (Ct) values of gene N according to treatment as well as Omicron BA.1 and BA.2 sub-lineages. (a) The survival probability plot for the event of negative PCR conversion amongst 60 Omicron-infected patients treated with nirmatrelvir and 195 Omicron-infected patients treated with sotrovimab (not adjusted on variables at baseline). The p for the log-rank test (p < 0.0001) indicates strong evidence of a significant difference between the survival curves. (b) Mixed model for Ct of gene N for 60 Omicron-infected patients treated with nirmatrelvir and 195 Omicron-infected patients treated with sotrovimab (not adjusted on variables at baseline). The p for the slope was <0.0001. After adjustment for age class and immunosuppression status at baseline, the p for the slope remained <0.0001. (c) The survival probability plots for the event of negative PCR conversion for 10 BA.1-infected patients treated with nirmatrelvir vs. 140 BA.1-infected patients treated with sotrovimab (the p for the log-rank test was 0.01) and for 49 BA.2-infected patients treated with nirmatrelvir vs. 43 BA.2-infected patients treated with sotrovimab (the p for the log-rank test was 0.1). The p was 0.06 for the comparison of BA.1- vs. BA.2-infected patients treated with sotrovimab and 0.84 for the comparison of BA.1- vs. BA.2-infected patients treated with nirmatrelvir. (d) Mixed model for Ct of gene N for 10 BA.1-infected and 49 BA.2-infected patients treated with nirmatrelvir and 140 BA.1-infected and 43 BA.2-infected patients treated with sotrovimab. The p for the slope was 0.003 for BA.1-infected patients and 0.001 for BA.2-infected patients. After adjustment for age class and immunosuppression status at baseline, the p for the slope remained at 0.003 and 0.001 respectively. Ct, cycle threshold.